Original Article

Real-life impact of early interferonβ therapy in relapsing multiple sclerosis†

  1. M. Trojano MD1,*,
  2. F. Pellegrini MDeStat2,
  3. D. Paolicelli MD1,
  4. A. Fuiani MD1,
  5. G.B. Zimatore MD1,
  6. C. Tortorella MD1,
  7. I.L. Simone MD1,
  8. F. Patti MD3,
  9. A. Ghezzi MD4,
  10. V. Zipoli MD5,
  11. P. Rossi MD6,
  12. C. Pozzilli MD7,
  13. G. Salemi MD8,
  14. A. Lugaresi MD9,
  15. R. Bergamaschi MD10,
  16. E. Millefiorini MD11,
  17. M. Clerico MD12,
  18. G. Lus MD13,
  19. M. Vianello MD14,
  20. C. Avolio MD15,
  21. P. Cavalla MD16,
  22. V. Lepore MD2,
  23. P. Livrea MD1,
  24. G. Comi MD6,
  25. M.P. Amato MD5

Article first published online: 28 MAY 2009

DOI: 10.1002/ana.21757

Issue

Annals of Neurology

Annals of Neurology

Volume 66, Issue 4, pages 513–520, October 2009

Additional Information

How to Cite

Trojano, M., Pellegrini, F., Paolicelli, D., Fuiani, A., Zimatore, G.B., Tortorella, C., Simone, I.L., Patti, F., Ghezzi, A., Zipoli, V., Rossi, P., Pozzilli, C., Salemi, G., Lugaresi, A., Bergamaschi, R., Millefiorini, E., Clerico, M., Lus, G., Vianello, M., Avolio, C., Cavalla, P., Lepore, V., Livrea, P., Comi, G. and Amato, M.P. (2009), Real-life impact of early interferonβ therapy in relapsing multiple sclerosis. Ann Neurol., 66: 513–520. doi: 10.1002/ana.21757

Author Information

  1. 1

    Department of Neurological and Psychiatric Sciences, University of Bari, Bari, Italy

  2. 2

    Department of Clinical Pharmacology and Epidemiology, Consorzio Mario Negri Sud, Santa Maria Imbaro, Chieti, Italy

  3. 3

    Department of Neurology, University of Catania, Catania, Italy

  4. 4

    Multiple Sclerosis Centre, Hospital of Gallarate, Gallarate, Italy

  5. 5

    Department of Neurology, University of Florence, Florence, Italy

  6. 6

    Department of Neurology, Hospital of San Raffaele, Milan, Italy

  7. 7

    Multiple Sclerosis Center, S. Andrea Hospital, University of Rome “La Sapienza,” Rome, Italy

  8. 8

    Department of Clinical Neurosciences, University of Palermo, Palermo, Italy

  9. 9

    Department of Oncology and Neuroscience, University G. d'Annunzio, Chieti, Italy

  10. 10

    Multiple Sclerosis Center, Neurological Institute C. Mondino, Pavia, Italy

  11. 11

    Department of Neurological Sciences, University “La Sapienza,” Rome, Italy

  12. 12

    Department of Neurology, S. Luigi Gonzaga Hospital, University of Turin, Turin, Italy

  13. 13

    Department of Neurological Sciences, 2nd University of Naples, Naples, Italy

  14. 14

    O. U. Neurology, Ca' Foncello Hospital, Treviso, Italy

  15. 15

    Department of Medical and Occupational Sciences, University of Foggia, Foggia, Italy

  16. 16

    Department of Neuroscience, University of Turin, Turin, Italy

*Department of Neurological and Psychiatric Sciences, University of Bari, Piazza Giulio Cesare 11-70124, Bari, Italy

  1. †

    Potential conflicts of interest: M.T. received honoraria for consultancy or speaking from Sanofi-Aventis, Biogen, and Bayer Schering, and research grants from Merck Serono; F.P.2 received honoraria for speaking from Biogen; I.L.S. received honoraria for speaking from Sanofi-Aventis and Biogen, and research grants from Sanofi-Aventis; F.P.3 received honoraria for speaking from Sanofi-Aventis and Merck Serono; A.G. received honoraria for speaking from Bayer Schering, Merck Serono, and research grants from Sanofi-Aventis, Biogen Dompè, and Merck Serono; C.P. received honoraria for consultancy or speaking from Sanofi-Aventis, Biogen, Bayer Schering, and Novartis, and research grants from Merck Serono and Sanofi Aventis; A.L. received honoraria for speaking from Biogen and research grants from Sanofi-Aventis, Merck Serono, Biogen, and Bayer Schering; E.M. received honoraria for speaking from Bayer Schering and research grants from Merck Serono, Sanofi-Aventis, Biogen-Dompè, and Bayer Schering; C.A. received honoraria for consultancy or speaking from Sanofi-Aventis, Biogen-Dompè, Bayer Schering, and Merck Serono; M.C. received honoraria for speaking from Bayer Schering; P.L. received research grants from Sanofi-Aventis, Merck Serono, and Biogen; G.C. received honoraria for consultancy or speaking from Teva Neuroscience Plough Corporation and Merck Serono; M.P.A. received honoraria for speaking from Merck Serono and Biogen, and research grants from Sanofi-Aventis, Merck Serono, Biogen, and Bayer Schering. The other authors declare that they have no conflicts of interest.

Publication History

  1. Issue published online: 8 OCT 2009
  2. Article first published online: 28 MAY 2009
  3. Accepted manuscript online: 28 MAY 2009 12:00AM EST
  4. Manuscript Accepted: 18 MAY 2009
  5. Manuscript Revised: 11 MAY 2009
  6. Manuscript Received: 20 FEB 2009

Funded by

  • Italian University and Research Ministry (MIUR). Grant Number: COFIN 2005–2006 M.T. Proselto Stzetegieo Regiolle Puque “Nurobío tech” PS 124

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

Get PDF (207K)

Options for accessing this content:

  • If you have access to this content through a society membership, please first log in to your society website.
  • If you would like institutional access to this content, please recommend the title to your librarian.
  • Login via Athens http://onlinelibrary.wiley.com/athens or other institutional login options http://onlinelibrary.wiley.com/login-options .
  • You can purchase online access to this Article for a 24-hour period (price varies by title)
    • If you already have a Wiley Online Library or Wiley InterScience user account: login above and proceed to purchase the article.
    • New Users: Please register, then proceed to purchase the article.

Please register to:

  • Save publications, articles and searches
  • Get email alerts
  • Get all the benefits mentioned below!

Register now >

Get PDF (207K)